BioMarin Pharmaceutical Reports Positive Results in Achondroplasia Treatment Trial

BioMarin Pharmaceutical has reported positive results from ongoing trials of VOXZOGO, its treatment for achondroplasia, a genetic condition causing dwarfism and stunted growth in children. Data shows that starting treatment before 2 years of age maximizes benefits, including height gains, better body proportions, and arm span. Over 5,000 kids in 50+ countries have used VOXZOGO, with strong results in Japan, Europe, and the US. BioMarin develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases.